Skip to content

A prospective, open-label, self-controlled study of ultrasound-guided intrafascial injection of platelet-rich plasma for the treatment of low back pain in adults

A prospective, open-label, self-controlled study of ultrasound-guided intrafascial injection of platelet-rich plasma for the treatment of low back pain in adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106691
Enrollment
Unknown
Registered
2025-07-28
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low back pain

Interventions

Single group:Intramuscular injection of 5 mL PRP into the thoracolumbar fascia in weeks 1, 2, and 3

Sponsors

The First Affiliated Hospital of Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for myofascial low back pain: There is regional pain in the lower back and lumbar area, palpable muscle taut bands are present, and referred pain or sensory changes are localized near a specific trigger point. The tender point within the taut band can be accurately identified. There may be mild muscle weakness or a certain degree of limitation in range of motion; 2. Moderate to severe pain, with a Visual Analog Scale (VAS) score >=4; 3. Patients are aged between 18 and 65 years; 4. Duration of symptoms exceeds 1 month; 5. Patients have a thorough understanding of the study details, and demonstrate good compliance and a high level of cooperation; 6. Informed consent has been obtained.

Exclusion criteria

Exclusion criteria: 1. Low back pain caused by any other reasons, including but not limited to lumbar disc herniation, lumbar spinal stenosis, ankylosing spondylitis, spinal tumors, spinal tuberculosis, spinal cord infections, etc; 2. Patients with severe diabetes or drug allergies; 3. Patients with fever, upper respiratory tract infection, or other infectious diseases; 4. Patients with systemic diseases or organ dysfunction; 5. Patients with coagulation disorders or those taking anticoagulant medications; 6. Patients with infections in the injection site or surrounding soft tissues; 7. Patients currently using corticosteroids or undergoing other treatments that may affect the observed outcomes of this study; 8. Patients with severe mental illnesses who are unable to cooperate; 9. Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
visual analogue scale,VAS;

Secondary

MeasureTime frame
OswestryDisability Index, ODI ;Japanese Orthopaedic Associationscores, JOA;Medical Outcom Study 36-Item Short-Form Health Survey, SF-36;

Countries

China

Contacts

Public ContactGao Bo

The First Affiliated Hospital of Air Force Medical University

gaobofmmu@hotmail.com+86 135 7280 1499

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026